The GBMD’s Chief-Scientist Dr Boominathan had proposed on June 16, 2006 (and 10, December, 2011) that p63 could play a role in insulin resistance, diabetes and obesity [Invention disclosure document (June 16, 2006) can be provided upon request]. Subsequently, Dr Boominathan had published on 1 September 2012 in the company website—http://genomediscovery.org–stating that p53/p63/p73-functions-as-regulator-of-insulin-secretion; p53/p63/p73 functions as a regulator of β cells survival during the progression of TypeI/II Diabetes1;p53/p63/p73 controls age or diet-induced weight gain/glucose intolerance; & TAp63/p73/p53 inhibits adipogenesis through its target miRNAs (http://genomediscovery.org/category/ideas/page/15/). Remarkably, in a rare and an astonishing coincidence (?), on Oct 3, 2012, Su X and Flores ER (from MD Anderson cancer center, Houston, USA) have published a paper entitled TAp63 Is a Master Transcriptional Regulator of Lipid and Glucose Metabolism in the high profile journal Cell Metabolism (5 year impact factor:17.770) (http://www.ncbi.nlm.nih.gov/pubmed/23040072). The above mentioned research paper was published nearly six years and four months (Oct 3, 2012) after the date of invention disclosure document (June 16, 2006) made by Dr Boominathan (http://genomediscovery.org/research/dr-boomis-scientific-caliber/).